Significant Differences Between Crohn’s Disease and Ulcerative Colitis Regarding the Impact of Body Mass Index and Initial Disease Activity on Responsiveness to Azathioprine: Results from a European Multicenter Study in 1,176 Patients

Holtmann, Martin H. ; Krummenauer, Frank ; Claas, Christina ; Kremeyer, Kristina ; Lorenz, Dirk ; Rainer, Olivia ; Vogel, Iris ; Böcker, Ulrich ; Böhm, Stephan ; Büning, Carsten ; Duchmann, Rainer ; Gerken, Guido ; Herfarth, Hans ; Lügering, Norbert ; Kruis, Wolfgang ; Reinshagen, Max ; Schmidt, Jan ; Stallmach, Andreas ; Stein, Jürgen ; Sturm, Andreas ; Galle, Peter R. ; Hommes, Daan W. ; D’Haens, Geert ; Rutgeerts, Paul ; Neurath, Markus F.

---

Alternative Links zum Volltext:DOIVerlag

---

Details

Dokumentenart:	Artikel
Titel eines Journals oder einer Zeitschrift:	Digestive Diseases and Sciences
Verlag:	SPRINGER
Ort der Veröffentlichung:	DORDRECHT
Band:	55
Nummer des Zeitschriftenheftes oder des Kapitels:	4
Seitenbereich:	S. 1066-1078
Datum:	2010
Institutionen:	Medizin > Lehrstuhl für Innere Medizin I
Identifikationsnummer:	Wert Typ 10.1007/s10620-009-0846-9 DOI
Stichwörter / Keywords:	INFLAMMATORY-BOWEL-DISEASE; RECEPTOR EXPRESSION; ABDOMINAL-TRAUMA; ADIPOSE-TISSUE; T-LYMPHOCYTES; TERM; INFLIXIMAB; MANAGEMENT; LEPTIN; TRIAL; Azathioprine; Crohn's disease; Ulcerative colitis; Disease activity; Body mass index
Dewey-Dezimal-Klassifikation:	600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin
Status:	Veröffentlicht
Begutachtet:	Ja, diese Version wurde begutachtet
An der Universität Regensburg entstanden:	Ja
Dokumenten-ID:	66214

Indiziert in

Web of Science

Bibliographische Daten exportieren

ASCII CitationAtomBibTeXData Cite XMLDataCite XML OAIDublin CoreDublin Core (LZV)EndNoteHTML CitationJSONJSON LDMETSMODSOPENAIREOpenAPCRDF+N-TriplesRDF+N3RDF+XMLReferReference ManagerSimple MetadataXMLopenCostxMetaDissPlus

---

Zusammenfassung

In a survey comprising 1,176 patients with inflammatory bowel disease (IBD) we recently showed that azathioprine (AZA) beyond 4 years is beneficial in ulcerative colitis (UC) patients and in a subset of Crohn's disease (CD) patients. Here, we show for the first time that azathioprine responsiveness depends on body mass index (BMI). The relationship is reciprocal in UC and CD, with a better ...

Zusammenfassung

In a survey comprising 1,176 patients with inflammatory bowel disease (IBD) we recently showed that azathioprine (AZA) beyond 4 years is beneficial in ulcerative colitis (UC) patients and in a subset of Crohn's disease (CD) patients. Here, we show for the first time that azathioprine responsiveness depends on body mass index (BMI). The relationship is reciprocal in UC and CD, with a better outcome in UC patients with a BMI<25 and in CD patients with a BMI>25. These observations are particularly interesting considering the evolving concept of a relationship between fatty metabolism and immune regulation. Additionally, we show that CD patients, but not UC patients, respond better to AZA when it is started in clinical remission. This observation may support data favouring a "hit hard and early'' regime in CD. Finally, we were able to demonstrate a decrease in the incidence of CD-related complications requiring surgery through treatment with AZA.

---

---

Metadaten zuletzt geändert: 19 Dez 2024 11:39

Nur für Besitzer und Autoren: Kontrollseite des Eintrags

Altmetric

Altmetric

Altmetric

Alternative Statistik (altmetrics)

Weitere Literatur (mittels CORE)

Weitere Literatur (mittels CORE)

Weitere Literatur (mittels CORE)

Weitere Literatur (mittels CORE)